Overweight, Obesity
Conditions
Keywords
pramlintide, Symlin, Amylin
Brief summary
This exploratory study is designed to evaluate various pharmacodynamic effects of subcutaneously (SC) infused or injected pramlintide in obese, nondiabetic male and postmenopausal female (not on hormone replacement therapy) subjects. The study will also assess the safety and tolerability of pramlintide administered by SC infusion or injection.
Interventions
Clear, colorless, sterile solution for SC administration
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
25 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Is \<6'3 (190.5 cm) tall and weighs \<300 lb (\ 136.3 kg) * Is obese with a body mass index (BMI) \>=30 kg/m\^2 to \<=45 kg/m\^2 and with a history consistent with progressive weight gain and development of obesity not secondary to drastic or traumatic initiating events (e.g., excessive weight gain due to cessation of smoking) * Is a nonsmoker (never smoked or has not smoked for at least 2 years) * Does not have a clinical diagnosis of diabetes * Has not had a major change in daily physical activity within 2 months prior to study start (e.g., initiation of an exercise program) * Usually consumes three major meals (morning, midday, and evening) each day and rarely (less than once a week) wakes up to eat during the night
Exclusion criteria
* Is currently enrolled in a weight loss program or plans to enroll in a weight loss or exercise program within the next 3 months * Is currently treated or expected to require or undergo treatment or has been treated within 2 months before screening with medications that are excluded: * Over the counter antiobesity agents including herbal supplements or prescription antiobesity agents approved for the long-term (including orlistat \[Xenical\] and sibutramine \[Meridia\]) and the short-term (including phentermine \[Adipex-P, Celltech, Pro-Fast SA, Pro-Fast SR, Fastin, Oby trim, Zantryl, Teramine, Phentride, Phentercot, Obephen, Oby-cap\], mazindol \[Sanorex and Mazanor\], methamphetamine \[Desoxyn\], diethylpropion \[Tenuate and Tenuate Dospan\], phendimetrazine \[Bontril, Prelu-2, Melfiat 105, Unicelles, X-Trozine, Plegine, Adipost, Obezine, Phendiet-105, PT 105\] and benzphetamine \[Didrex\]) treatment of obesity * Systemic steroids by oral, intravenous, or intramuscular route or potent topical steroids that are known to result in high systemic absorption * Alpha- or Beta-Blockers, centrally acting sympathicolytic or sympathicomimetic agents, reserpin, guanethidine, etc. * Psychotropic medications (e.g., tricyclic antidepressants, monoamine oxidase \[MAO\] inhibitors, selective serotonin reuptake inhibitors \[SSRIs\], neuroleptics, lithium, and benzodiazepines) * Hypnotic-sedative medications or medications that may affect sleeping behavior including medications containing caffeine * Drugs that directly affect gastrointestinal motility, including but not limited to: metoclopramide (Reglan®) and cisapride (Propulsid®); and macrolide antibiotics such as erythromycin and newer derivatives * Has received any investigational drug within 3 months before study start * Has participated previously in a study using pramlintide
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate various pharmacodynamic effects (including effects on body weight, food intake, and other parameters) of subcutaneously (SC) infused or injected pramlintide in obese subjects. | 73 Days |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the safety and tolerability of SC infused or injected pramlintide in obese subjects. | 73 Days |
Countries
United States
Outcome results
None listed